RxDoctor Payments Data

Alan Stern, MD

Ophthalmology · New Britain, CTNPI 1740277714

Payments from drug & device makers

$1,454in general payments, 2019–2025

Across 30 payments — averaging $48.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$511
  • Johnson & Johnson Surgical Vision, Inc.$153
  • Sun Pharmaceutical Industries Inc.$140
  • Bausch & Lomb Americas Inc.$125
  • Glaukos Corporation$123
  • Novartis$102
  • plus $300 from 8 others

What the payments were for

  • Food & beverage$1,11577%
  • Gifts$33923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,454 in reported general payments places this provider in the 55th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$91,353
Medicare patients
447
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$58,996
LumiganBimatoprost62$40,732
XiidraLifitegrast17$27,529
RhopressaNetarsudil Mesylate23$20,376
Cyclosporine13$12,513
CombiganBrimonidine Tartrate/Timolol19$12,472
Travoprost59$12,331
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$7,918
ZirganGanciclovir13$6,013
Tobradex StTobramycin/Dexamethasone25$5,701
Prednisolone Acetate88$4,058
Brimonidine Tartrate32$3,207
CiloxanCiprofloxacin Hcl11$2,943
Latanoprost198$2,562
Loteprednol Etabonate14$2,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$81$112,200122 claims
Bausch & Lomb Americas Inc.Xiidra, Zirgan$125$33,54130 claims
Aerie Pharmaceuticals, Inc.Rhopressa$38$20,37623 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$44$2,39714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →